论文部分内容阅读
目的:观察参一胶囊对非小细胞肺癌的辅助治疗作用。方法:３９例非小细胞肺癌气虚证患者,分为联合组(２３例),化疗(ＥＰ方案)＋参一胶囊;对照组(１６例),仅进行化疗(ＥＰ方案)。结果:与对照组相比,联合组气虚证和症状(神疲乏力、呼吸气短、少气懒言、纳谷少馨及自汗等)以及近期客观有效率均有明显改善(Ｐ＜０．０１);生活质量改善,表现为Ｋａｒｎｏｆｓｋｙ评分及体重均有提高(Ｐ＜０．０５);血液学毒性(主要为白细胞)明显减轻(Ｐ＜０．０５)。结论:参一胶囊用于治疗非小细胞肺癌气虚证,可以改善临床收益疗效,提高生活质量,增加化疗疗效和减轻其血液学毒性。
Objective: To observe the effect of Shenyi capsule on adjuvant therapy of non-small cell lung cancer. Methods: Thirty-nine patients with NSCLC were divided into the combined group (23 cases), chemotherapy (EP regimen) and Shenyi capsule, and the control group (16 cases) were treated with chemotherapy only (EP regimen). RESULTS: Compared with the control group, the qi deficiency syndrome and symptoms (weakness, shortness of breath, shortness of breath, lazyness, Nagu Shaoxin, spontaneous perspiration, etc.) and recent objective effectiveness were significantly improved in the combined group (P<0.01). Quality of life improved with Karnofsky score and weight gain (P<0.05); hematologic toxicity (mainly white blood cells) was significantly reduced (P<0.05). Conclusion: Shenyi capsule can be used for the treatment of qi deficiency in non-small cell lung cancer. It can improve the clinical benefit, improve the quality of life, increase the efficacy of chemotherapy and reduce the hematological toxicity.